These are promising results– Professor Kristian Helin, Director General of ICR

Now, faced with these results “clinically significant”, but marked with a “lack of statistical significance”, Professor Kevin Harrington, professor of biological cancer therapies at ICR, announced to our British colleagues that a “longer follow-up to see if we can demonstrate a survival benefit for all patients in the trial” would take place soon.

defends the ambition of information
free,
verified and accessible to all thanks to the income of the
advertising .

To help us maintain this free service you can “change your choice” and accept all cookies.

.

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.